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Abstract: Peptidoglycan degrading enzymes are of increasing interest as antibacterial agents,
especially against multi-drug resistant pathogens. Herein we present a review about the biological
features of virion-associated lysins and endolysins, phage-derived enzymes that have naturally
evolved to compromise the bacterial peptidoglycan from without and from within, respectively.
These natural features may determine the adaptability of the enzymes to kill bacteria in different
environments. Endolysins are by far the most studied group of peptidoglycan-degrading enzymes,
with several studies showing that they can exhibit potent antibacterial activity under specific
conditions. However, the lytic activity of most endolysins seems to be significantly reduced when
tested against actively growing bacteria, something that may be related to fact that these enzymes
are naturally designed to degrade the peptidoglycan from within dead cells. This may negatively
impact the efficacy of the endolysin in treating some infections in vivo. Here, we present a critical
view of the methods commonly used to evaluate in vitro and in vivo the antibacterial performance of
PG-degrading enzymes, focusing on the major hurdles concerning in vitro-to-in vivo translation.
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1. The Antibiotic Resistance Crisis
Bacterial infections have always impacted human health and are among the leading cause of
death [1,2]. This problem is recently becoming more critical, as we witness an unprecedented rise of
multi-drug resistant pathogens that are considered by the Infectious Diseases Society of America and
the European Society of Clinical Microbiology and Infectious Diseases one of the greatest threats to
human health of the new millennium [3–5].
ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa and other Enterobacteriaceae species) are the leading group among
these so-called superbugs, that can rapidly gain resistances to several classes of antibiotics and are
able to cause a variety of nosocomial infections (such as bacteremia, wound and skin infections) [6,7].
The reduced susceptibility towards antibiotics makes the treatment of ESKAPE infections extremely
difficult and scientists are now trying to widen the repertoire of alternative antibacterial agents.
Phage-encoded enzymes that have the capacity to degrade the major component of the bacterial cell
wall (CW), the peptidoglycan (PG), or murein, represent a promising alternative class of antibacterial
agents with increasing prominence [8,9]. Almost two decades after the first experimental validation
of their antibacterial potential [10], we present the biological, molecular and antibacterial properties
of the different phage-derived PG-degrading enzymes and highlight some advantages, constraints
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and future considerations useful when aiming at using the antibacterial potential of these enzymes
(“enzybiotics”) against infectious diseases in vitro and in vivo.
2. Peptidoglycan-Degrading Enzymes—An Emerging Class of Antibacterial Agents
2.1. Biology and Diversity
Tailed phages are ubiquitous viruses that specifically infect bacteria in order to replicate. At the
end of the reproductive cycle these viruses lyse the host cells to release the descendant virus particles
to the extracellular space. Therefore, during the lytic cycle a phage needs to breach the bacterial CW
twice, first to deliver its DNA (and sometimes a few proteins) to the host cell cytoplasm and at the end
to liberate the virion progeny. Phage PG-degrading enzymes are employed in both steps. Those acting
during viral DNA entry are carried in the virus particle and are often called virion-associated lysins
(VALs) or virion-associated peptidoglycan hydrolases [11]. At the beginning of phage infection, VALs
attack the CW of host cells from outside and are thought to promote a local degradation of the murein
to facilitate penetration of the phage tail tube and injection of the viral DNA [12]. Nevertheless, the fact
that some VALs like those from S. aureus phage phi11 and E. coli phage T7 showed to be dispensable for
phage infection in the lab suggests that they may confer an advantage only under certain physiological
conditions [13,14].
The enzymes responsible for host cell lysis are synthesized in the cytoplasm of infected bacteria
and are designated endolysins. At the end of phage infection, most endolysins require the action of
another phage-encoded protein—the holin—to be able to cross the cytoplasmic membrane and gain
access to the CW. Holins are usually small hydrophobic proteins that oligomerize in the bacterial
cytoplasmic membrane and, at the appropriate time, they form lethal holes that are large enough to
allow endolysin escape to the CW. Once in this cell compartment, endolysins quickly degrade the PG
polymers of the killed host bacteria, leading to abrupt osmotic cell lysis and subsequent release of
progeny phages [15,16].
VALs and endolysins have evolved multiple enzymatic activities to specifically degrade the PG.
The PG polymer is composed of alternating N-acetylmuramic acid (MurNAc) and N-acetylglucosamine
(GlcNAc) residues linked by β-1,4 glycosidic bonds. Adjacent glycan strands are cross-linked by short
interconnected stem peptides, each of them linked to MurNAc residues through an amide bond
involving the first amino acid of the peptide stem (usually L-alanine [17]). Depending on the bonds
that VALs or endolysins cleave, their activity can be categorized into different classes: lysozyme,
transglycosylase, glucosaminidase, amidase or endopeptidase [18]. The first three classes cleave the
glycosidic bonds in the glycan chains, amidases hydrolyze the amide bond connecting MurNAc to the
peptide stems and endopeptidases cleave within the peptide moiety.
Endolysins can have a globular or a modular design [18,19]. In the first case, the lytic enzymes
essentially correspond to the single enzymatic catalytic domain (ECD) responsible for cleaving a
specific PG bond. In the most common modular structure, one or two N-terminal ECDs are connected
by a flexible linker to one or more cell binding domains (CBD), which are responsible for recognizing
specific epitopes on the CW. This modular configuration is most commonly found in endolysins of
phages infecting Gram-positive bacteria and mycobacteria [8,18,20]. Nevertheless, few exceptions
with modular structure have been reported in Gram-negative systems but, interestingly, with inverted
orientation of the functional domains [21,22]. The diversity of endolysins is notorious with 24 and
13 different types of ECDs and CBDs, respectively, and 89 unique architectural organizations
identified [18]. The most accepted hypothesis for the presence of CBD in most endolysins of phages
infecting Gram-positive hosts, is that by being bound to the CW debris after cell lysis, the enzymes
will not diffuse and destroy nearby potential hosts, therefore enabling progeny phages to initiate
new infection rounds [23]. Since Gram-negative bacteria have an outer membrane (OM) protecting
the internal PG, the endolysins released at the end of the phage lytic cycle should not compromise
non-infected cells.
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VALs are structurally much more diverse and usually larger (37–252 kDa) than cognate endolysins
(15–40 kDa). They may confer structural and functional roles to phage virus particles in addition to
murein cleavage and some are found as oligomers in the virion structure. VALs from Gram-positive
systems frequently display two distinct ECDs to degrade the PG, likely as a response to the thick PG
layer found on their hosts. There is one particular ECD, the endopeptidase ECD of the M23 family,
which is frequently present in VALs and rarely found in endolysins. Interestingly, this domain is
responsible for the PG-degrading activity of the bacteriolysins lysostaphin and enterolysin A [24,25],
which also act from without and on actively growing cells. VALs however, usually lack CBDs [26].
The absence of CBDs in VALs could be explained by the fact that they are often subdomains of larger
proteins or belong to virion structures that promote proximity of the VAL to the CW [26]. In fact, VALs
often form part of tail fibers, tape measure proteins and baseplates (e.g., lactococcal phage TP901-1,
S. aureus phage phiIPLA35 and E. coli phage T4, respectively) [27] but can also be internal capsid
proteins (e.g., in E. coli phage T7 and P. aeruginosa phiKMV) [28].
2.2. Enzybiotics Lytic Activity and Efficacy
VALs lytic activity is responsible for the “lysis from without” phenomenon, first described
in 1940, due to multiple phages puncturing [29]. In Gram-positive hosts, VALs from lactococcal
phages Tuc2009 and TP901-1 and Bacillus subtilis phages SP-β and phi29 were tested and proved to
degrade the bacterial CW [30,31]. Interestingly, the VALs of all these phages carry at least one ECD
of the M23 family (peptidase). In the lactococcal phages this domain was shown to facilitate CW
penetration and phage genome delivery, particularly to stationary phase cells that carry an extensively
cross-linked CW [30]. VALs of S. aureus-infecting phages phiIPLA88 and P68 were shown to reduce
∼99% the cell counts of S. aureus clinical isolates after 20 min exposure, including methicillin-resistant
strains [32,33]. Studies have also demonstrated the bifunctional lytic activity of phiMR11 VAL, bearing
cysteine, histidine-dependent amidohydrolase/peptidase and lysozyme activities, by purifying each
domain as recombinant proteins [34]. In Gram-negative pathogens, VALs activity has also been
confirmed mostly on Pseudomonas hosts [35–37]. Using bacterial cells with permeabilized OM by
chloroform treatment [21], the muralytic activity of these VALs showed to be exclusively against
Gram-negative pathogens and in most cases independently of the phage host (e.g., E. coli, P. fluorescens,
P. putida). This is explained by the conserved composition and structure of the PG (chemotype A1γ)
among Gram-negative bacteria, in contrast with the diverse chemotypes found in Gram-positives [38].
Some VALs are also highly thermostable. For instance, the P. aeruginosa phiKMV VAL could retain
>20% of its activity after 2 h at 100 ◦C and even after autoclaving. S. aureus phage HydH5 VAL can
resist 100 ◦C for 5 min [32]. This is probably related with their structural nature, evolved to endure
harsh external conditions in order to maintain the phage infectivity. Additionally, VALs have been
shown to synergize with endolysins and antibiotics [39,40]. Protein engineering to improve VALs
performance has also been successful, as described for few S. aureus and Enterococcus faecalis phage
enzymes [39,41–43]. Taken together, VALs have several appealing characteristics for biotechnological
applications, particularly for those where thermal processing is required.
Endolysins have emerged over the last years as an exciting new antimicrobial and are far more
studied than VALs. The first report of an activity of a recombinant endolysin dates back to 1959 [44].
Since then, nanogram quantities of certain endolysins have showed to be efficient in eliminating
bacterial suspensions in seconds [10] and numerous studies have proved their antibacterial potential
in vitro, for example against methicillin-resistant and multidrug-resistant S. aureus (endolysins LysK
and MV-L, respectively) [45,46], and towards vancomycin-resistant E. faecalis and E. faecium (endolysin
PlyV12) [47]. Endolysins have also been used in cocktails or in combination with antibiotics to
eliminate pathogenic bacteria. Antibiotic-resistant S. pneumoniae strains have been targeted using
Cpl-1 and Pal endolysins, which share the same target specificity but have different catalytic
activities [48]. Synergistic effects have also been demonstrated with the Cpl-1 endolysin and penicillin
or gentamicin antibiotics against S. pneumoniae strains with different levels of susceptibilities to
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penicillin [49]. Moreover, the need to develop endolysins with desired or enhanced properties
for several biotechnological applications has led to the creation of tailor-made enzymes by adding,
truncating or swapping functional domains (engineering strategies and major outcomes are reviewed
in [50,51]). Endolysin engineering was for the most part pioneered by studies that highlighted the
modular character of the lytic enzymes of S. pneumoniae and its phages. It was shown that ECDs
and CBDs from different enzymes could be exchanged to generate chimeras that retained the native
cleavage and binding properties of the individual modules [52]. In the case of staphylococcal phage
endolysins, similar modifications were made to overcome solubility problems [53,54]. The CBD
truncations of the S. aureus phage LysK and Streptococcus agalactiae PlyGBS endolysins resulted in 2-
and ~25-fold increase in muralytic activity, respectively [55,56]. Elimination of endolysin CBD may
additionally lead to the expansion of the enzymes’ spectrum of activity [57–59]. In an inverse approach,
the addition of an extra CBD to the Listeria phage endolysin Ply500 increased CW binding affinity by
approximately 50-fold, which translated in enhanced lytic activity in high salt conditions [60].
2.3. Recent Developments for Endolysins Targeting Gram-Negative Bacteria
While phage-derived PG-degrading enzymes have been shown to efficiently work exogenously
as recombinant proteins to kill Gram-positive bacteria pathogens (for extensive review see [61]), their
application against Gram-negative pathogens is more limited. As mentioned above, the presence of
an OM acts as a protective barrier that prevents the enzymes added exogenously reaching the PG,
making their application more challenging. In view of the conserved Gram-negative bacterial PG
structure, the application of PG-degrading enzymes on these bacteria could be of great importance
in the microbial control. Only recently, several studies have addressed this problem by (i) exploring
the “natural” ability of some endolysins to kill Gram-negative bacteria, particular those possessing
positively charged segments that are able to disorganize or even disrupt the OM (e.g., T4 and
LysAB2 endolysins) [62,63], (ii) combining endolysins (e.g., EL188 and Lys68 endolysins) with
OM permeabilizing agents such as EDTA and organic acids that displace divalent cations and
destabilize the membranes [64–66], or (iii) genetically engineering endolysins like the so called
Artilysins [67], which carry lipopolysaccharide-destabilizing peptides with a polycationic, hydrophobic
or amphipathic nature (e.g., SMAP-29 and polycationic nonapeptide), to allow passage of the
recombinant proteins through the OM [67,68]. These strategies were proven successful in vitro against
a number of different pathogens, like Salmonella, E. coli, A. baumannii and P. aeruginosa. Artilysins
(e.g., LoGT-008) have also been successfully applied in human keratinocytes and Caenorhabditis elegans
models to control infections [67].
3. From Discovery to Therapeutic Application
There is a great diversity of PG-degrading enzymes that can be harnessed to develop antibacterial
agents. Figure 1 presents a flowchart with the typical steps underlying the exploration of phage lytic
proteins. The process usually starts with in silico identification of genes encoding PG-degrading
proteins in phage genome sequences. PG-degrading enzymes are well conserved and therefore easy
to find bioinformatically using BLAST-based tools [69]. The next steps involve enzymes cloning,
expression and purification of candidates, before evaluation of their in vitro and in vivo performance
using several different possible methods as follows.
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3.1. In Vitro Performance Evaluation
The in vitro assessment of PG-degrading activity can be performed directly or indirectly
using different techniques. The spot-on-lawn method, the turbidimetry assay and zymogram
analysis are most commonly used to directly evaluate lytic activity. Assessment of the remaining
number of Colony Forming Units (CFUs), following enzyme testing and determination of minimum
inhibitory concentrations (MIC) are often used to assess the impact of the enzybiotics on cell viability.
These methods that distinctively evaluate bacteriolytic, bactericidal and bacteriostatic activities of
enzybiotics have their own limitations, with some yielding inconsistent results when applied to certain
lytic enzymes. For example, for reasons that are still unknown, some enzymes with high bacteriolytic
activity seem not amenable to standard MIC determinations [8,70]. The selected protocol(s) will
depend on the aim, state of enzyme characterization and easiness of implementation.
Due to its simplicity, the spot-on-lawn method is probably the first method performed to validate
the putative muralytic function of a novel enzyme. There are two variants of this assay: (1) a diluted
bacterial inoculum is spread on agar plates using overlay techniques and afterwards defined amounts
of the enzybiotic in a small volume (usually 10 µL) are spotted on the lawn. Observation of clear halos,
usually after overnight incubation, is indicative of growth inhibition as result of lytic activity [43].
Nevertheless, with Gram-positive bacteria this method can give false results if density of bacterial
lawns is not controlled. Heavy growth of these bacterial cells can make them relatively resistant
to the enzyme killing effect; (2) a concentrated bacterial inoculum is incorporated in an agarized
physiologic buffer to prepare a ready-to-use, dense bacterial lawn. After spotting the enzybiotic,
the bacteriolytic activity is revealed by the appearance of lysis zones after a few minutes or hours of
incubation. This assay is useful to quickly determine the lytic spectra of the enzymes. In the case of
Gram-negative species, an additional step involving treatment with chloroform vapors is needed to
permeabilize the OM [65].
The turbidimetry assay is probably the most used method. Enzybiotics are incubated with
suspensions of live, dead cells or PG extractions as substrate. In most cases live bacteria are used,
which are grown to exponential phase and usually adjusted to an optical density of 1.0 prior to
incubation with defined amounts of enzyme. Of note, in the vast majority of the cases the cell
suspensions are prepared in buffered solutions, which are conditions not supporting bacterial growth
and poorly mimicking in vivo infection contexts. Again, in Gram-negative bacteria, a pre-treatment
using chloroform saturated buffer is needed to permeabilize the OM prior to start the kinetic assay [71].
Lysis is measured as a decrease of optical density over time which can be assessed by i) the steepest
slope of the killing curve (i.e., unit is defined by ∆OD/min) [70,72] or by quantification of the amount
of protein necessary to drop a percentage of the optical density relative to its initial value (i.e., unit is
defined by a drop of density, e.g., of 50%) [10,54,73]. The use of different enzyme activity definitions
makes comparison between studies difficult, therefore there is a need for a uniform unit definition
for accurate quantification of muralytic activity [72]. It must be stressed that the turbidimetric assay
cannot be applied to assess the killing activity of certain endolysins. A good example is the endolysin
of Paenibacillus larvae phage phiIBB_Pl23 which can only reduce the optical density of cultures starting
with an OD620 of 0.6 and not more [74]. Another example are endolysins of Listeria infecting phages
that produce efficient lysis only if cells are previously frozen, probably to aid the degradation of their
thick PG layers [60].
The changes in CFUs is often used to assess the enzymes’ antibacterial properties. The lytic agents
are added to live bacterial suspensions of known concentrations, again generally prepared in buffers,
and incubated during a period of time (usually minutes or hours). CFU counts are then compared with
control groups and the antibacterial activity is usually expressed as a log reduction or a percentage of
killing. Although this assay gives an important notion of the bacterial load that the enzyme is able
to eliminate, it has the limitation of not being able to distinguish between not viable and viable but
non-cultivable cells.
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MIC assay aims at finding the lowest enzybiotic concentration that completely inhibits the
visible planktonic growth of a microorganism. Variations of this assay include the minimum
bactericidal concentration and the minimum biofilm eradication concentration, for determination
of the minimum concentrations leading to undetectable CFUs after targeting suspended and sessile
cultures, respectively [75,76]. In the MIC assay, serial dilutions of the lytic agent are distributed into
wells of a microtiter plate and mixed with a defined concentration of cells prepared in culture media
(usually up to 105–106 CFU/mL). MIC is given as the lowest enzyme concentration leading to no visible
bacterial growth after overnight incubation. This data is useful to compare enzymes’ performance
with antibiotics, which are routinely tested this way, providing also a starting point for setting doses
to be used in in vivo assays [77]. MIC assays have been particularly used to assess the antimicrobial
potential of engineered lytic enzymes and to study the synergistic effect when these are combined with
conventional antibiotics [54,68,78].
Zymograms are a modified version of an SDS-PAGE gel where autoclaved bacterial cells or
extracted PG are incorporated in the gel matrix to achieve haziness. After electrophoresis, the presence
of PG-degrading enzymes is revealed by the appearance of transparent bands (lysis zones) after
protein renaturation, which is achieved by SDS removal with rinsing water of buffer. This more
hard-to-implement assay is more useful to pinpoint the enzymes according to their molecular weight
and therefore also used to screen PG-degrading activity in blind expression libraries. Like the
spot-on-lawn method however, the activity assessment is only qualitative [79,80].
3.2. In Vivo Performance Evaluation
The majority of enzybiotics is in pre-clinical phase trials and has been tested to target Gram-positive
bacterial pathogens that include Streptococcus spp. [10,48,55,73,78,81–93], S. aureus [45,54,94–107],
Bacillus anthracis [108,109] and E. faecalis [110] and more recently the Gram-negative pathogens
P. aeruginosa [111] and A. baumannii [112,113]. According to literature, there is only one report showing
the efficacy of a VAL (P128) against S. aureus in vivo. However, as discussed by São-José [51] there are
several engineered chimeric enzymes sharing the ECD of Ply187, which is most probably a VAL of
the staphylococcal phage 187 and not the phage’s endolysin as previously reported. Ply187-derived
chimeolysins tested in vivo include Ply187AN-KSH3b, ClyH and ClyF [94,101,114,115].
Animal models of systemic infection have been the most used to study the in vivo potential
of enzybiotics, which are administrated by parenteral way to treat bacteremia. A compilation of
these in vivo experiments is presented in Table S1. Here, animals are challenged with deadly doses
of bacteria, treated with endolysins few hours post infection and readouts account mostly for the
number of surviving mice after treatment and the development of neutralizing antibodies. There are
no standardized methods to assess endolysins’ performance in vivo, animals are challenged with
different infectious doses of bacteria and different administration routes and timings are employed,
which render the comparison between results difficult. Cpl-1 is a good example of mixed outcome
reports (Table S1). In one study, 100% Cpl-1-treated mice survived when Cpl-1 was added intravenously
1 h-postinfection [73]. In a second independent study, only about 30% Cpl-1-treated mice survived
when the enzyme was added intraperitoneally 1 h-post infection [78]. Another study demonstrated
that Cpl-1 failed when added by intraperitoneal injection [48]. Nevertheless, other enzymes have
repeatedly shown success in treatment of systemic infections when administered intraperitoneally,
such as PlyG, MV-L, CF-301, Ply30 and PlyF307 targeting B. anthracis, S. aureus, S. pyogenes, S. suis
and A. baumannii, respectively (Table S1). Most importantly, the majority of in vivo efficacy studies
treat animals a few hours after initiation of infection, usually 1 h after bacterial inoculation (Table S1),
therefore only mimicking treatment of early bacteremia, a rare clinical occurrence. In these assays,
the enzybiotics essentially provide a protective effect, rather than functioning as an effective therapy
against well-established infections. The few studies that report different administration times show
that treatment fails when enzymes are added latter. For example, mice with pneumococcal bacteremia
treated 1 h post infection with the endolysin Cpl-1 showed 100% survival compared to the 20% survival
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of the non-treated group [73]. However, in advanced bacteremia (5 h and 10 h post infection), the same
enzyme was able to extend the lifespan but not to increase mice survival rates, when compared to
control groups. LysGH15 is another extensively studied endolysin to control invasive MRSA-infected
mice. In two independent studies, it was shown that either i.p. or i.v. single doses of LysGH15
(50 µg/mouse) were sufficient to protect mice against lethal systemic MRSA infections [103,116].
Nevertheless, it was also clear that survival rates were time dependent. LysGH15 could only rescue
100% of bacteremic mice if added 1 h after bacterial challenge, being the survival rate significantly
decreased to 20% when added 4 h later. Other studies reporting enzyme administrations 1 h and
3 h-post infection have also shown a mild activity (Table S1). This is the case of plyF307 for instance,
that when applied 1 h after infecting mice with A. baumannii resulted in 50% of survival compared with
the 10% of survival of the control group [112]. The fact that endolysins when applied systemically could
face short half-life, immunogenicity, allergenicity, proinflammatory responses and inability to target
intracellular bacteria is well discussed elsewhere [50]. Herein we will focus on the lower efficiency of
endolysins that is frequently observed under conditions promoting robust bacterial growth and which
could explain some of their limitations observed in vivo.
4. In Vitro to in Vivo Translation
4.1. Hurdles
There are hundreds of reports supporting the antibacterial activity of endolysins in vitro and a
considerable number of these enzymes have also been tested in vivo. Still, a major question remains:
is the capacity to kill bacteria from without an intrinsic feature of endolysins and are they all suitable
for use as enzybiotics? The use of endolysins as enzybiotics builds on the idea that they should be able
to efficiently lyse bacteria from without, as long as contact to the CW is granted. However, this premise
conflicts with the natural mode of action of endolysins, which have evolved to act from within and
after holin-mediated collapse of the membrane potential, that is, after cell death (see Section 2.1).
As such, the conditions used to evaluate the antibacterial efficacy of a given enzyme in vitro may
have great impact on results and therefore caution should be taken when making extrapolations to
in vivo scenarios.
Most in vitro studies to assess the bactericidal potential of enzybiotics employ target cells
resuspended in buffered solutions, that is, in conditions not supporting bacterial growth. The few
examples of enzymes tested in more complex and realistic bio-matrixes have shown limited or absence
of activity (see below). Therefore, the enzybiotic antibacterial efficacy obtained in vitro may not
be translated in the complex environments also observed in vivo. As already mentioned, the cases
where in vitro efficiency seems to translate to in vivo are mostly observed when lytic enzymes are
administrated to animals soon after bacterial challenge. Possibly, because bacteria are usually washed
with buffers prior injecting them into the animals, cells may become in a transient “lag” state that
is more susceptible to the enzymes’ lytic action (analogous to the in vitro lysis of buffer-suspended
cells). In time, the bacterial cells eventually adapt to the new nutrient conditions in the host, becoming
metabolic more active and eventually more resistant to the action of enzymes (which are known to fail
when added several hours after bacterial challenge in systemic infections). Endolysins are also routinely
characterized in vitro using exponential growth phase cells and not cells in older physiological states.
In some cases, stationary-phase cells were shown to be less susceptible to the enzymes’ lytic action,
probably due to cell envelope structural or chemical modification of the PG [65,92]. It is known that
PG maturation and remodeling occurs in stationary cells and can involve the acetylation and/or
N-deacetylation of glycan chains and amidation of peptides, modifications that may confer resistance
to lytic enzymes [117]. The relevance of these observations when passing to in vivo scenarios is still
unknown. These hurdles have been shown both with Gram-positive and Gram-negative pathogens.
Recent studies have highlighted the influence of the cell energy state and growth conditions in
bacterial susceptibility to some endolysins. Lys170, an enterococcal endolysin harboring an N-terminal
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ECD and a C-terminal CBD, could efficiently lyse viable E. faecalis cells grown to exponential stage
and suspended in a physiologic buffer before enzyme treatment [43]. However, the same Lys170
amounts failed to lyse or prevent growth of cells suspended in nutritional medium like TSB. Possible
inhibition effects of TSB components were discarded by simultaneously treating cell suspensions with
Lys170 and the lantibiotic nisin, which induces membrane pore formation and consequently cell death.
Cells killed by the nisin action revealed to be fully susceptible to the Lys170 lytic action, indicating that
TSB components did not significantly interfere with the endolysin activity. Authors hypothesized that
it could be a result of the inability of the endolysin to act on actively growing cells, as buffers do not
support cell growth.
The fact that dividing and fully energized bacteria are less susceptible to endolysin attack makes
biological sense because, as already mentioned, these enzymes are naturally designed to cleave the
PG of cells killed by the action of cognate holins. This hypothesis gained further support after studies
with the endolysins of two well-known phages, the Bacillus subtilis phage SPP1 and the S. aureus phage
phi11 [118]. The investigation showed that conditions inducing cytoplasmic membrane depolarization
(holin action, membrane ionophores or nutrient depletion) could dramatically increase bacterial
susceptibility to the endolysins attacking the CW either from within or from without. The results
of this work also indicated that the capacity of energized cells to counteract endolysin attack may
vary significantly depending on the tested bacterium/endolysin pair and growth conditions. Overall,
the idea that emerged is that the lytic efficacy of endolysins may be significantly conditioned by
the energetic state of target cells, something that should be verified when exploring these agents as
enzybiotics. As discussed in the referred studies, a relationship between the cytoplasmic membrane
energy state and the susceptibility of bacteria to PG-degrading enzymes (either endogenous or
exogenous) has been reported in many different contexts.
Although the OM of Gram-negative bacteria is generally viewed as a barrier that blocks access
to the CW of exogenously-added enzymes, several examples of endolysins that spontaneously
cross the OM and exert lytic activity were reported [21,62,63,119,120]. Similarly, these enzymes
have also been tested in artificial conditions using bacteria suspended in buffer and activity is not
reproduced when tested on different environments. For instance, we have recently cloned and tested
the antibacterial activity of the Acinetobacter phage Vb_MAb_B9 endolysin in different biomatrixes.
The endolysin was able to reduce more than three orders of magnitude the cell counts of a bacterial
suspension prepared in Hepes. However, in other media like PBS or TSB it lacked antibacterial
activity [121] A peptide-modified endolysin (PlyA) was shown to reduce more than five orders of
magnitude the counts of logarithmic phase A. baumannii cells suspended in Tris-HCl buffer. Yet, it was
completely inactive when tested in biomatrixes such as pasteurized milk, human serum and different
bacterial culture media [122]. In addition, PlyA could kill buffer-suspended, A. baumannii stationary
cells only when in presence of OM permeabilizers. Another example is the A. baumannii phage
endolysin PlyF307, which was able to reduce more than 3 orders of magnitude the cells collected
from exponentially growing cultures but only one order of magnitude in case of stationary phase
bacteria [112]. Therefore, several reports indicate that endolysins’ high performance in vitro might not
translate into in vivo efficacy, where cells are not in the optimal conditions for enzybiotic activity.
4.2. Possible Solutions
4.2.1. Complementary Screening Tests to Search for the Best Enzybiotic
To better assess the enzybiotics’ potential for in vivo applications, their performance should be
evaluated not only under different ranges of pH, temperatures and ionic strengths but also using
different environment conditions and cells in different physiological states mimicking a more likely
in vivo scenario. Furthermore, experiments using human serum and simpler animal models (C. elegans,
G. mellonella, Drosophila melanogaster or zebrafish) [123–126] could also be considered as an alternative
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to evaluating the antimicrobial activity of enzymes considered to treat systemic infections, before using
more complex mammalian systems, such as murine models.
4.2.2. Using VALs
VALs, as opposite to endolysins, need to maintain activity in several environmental conditions and
against different physiological states of the host bacterium to allow phage infection and proliferation.
With this hypothesis in mind, Proença et al. [43] generated a chimeric protein (EC300) harboring the
M23 ECD of the VAL Orf73 and the CBD of the endolysin Lys170, both from the E. faecalis phage
F170/08. In contrast to the endolysin, the chimeolysin showed efficient lytic action from outside
against dense cell cultures in nutritional medium. Another important study in this field was the
characterization of the coliphage T7 VAL. Despite the predicted role of this enzyme to help the phage
tail to penetrate the PG-mesh structure at onset of infection, its function is dispensable when phage
infects the host under optimal laboratory conditions [14]. Interestingly, the T7 VAL function is only
required when host cells have the PG highly cross-linked, namely when in stationary or when growing
at low temperatures. This demonstrates that VALs are adapted to cleave the PG of host cells under
physiological states different from logarithmic growth, which is routinely tested but not always
present in human infections. This hypothesis is further supported by the characterization of the
lactococcal phages Tuc2009 and TP901-1 VALs, both harboring a M23 peptidase ECD and which were
proved to be essential for phages to efficiently infect stationary phase cells [30]. As already noted,
the M23 ECD is almost absent in endolysins but seems to be frequently present on VALs and on other
non-viral PG-degrading enzymes naturally designed to act on the bacterial CW from the outside
(bacteriolysins like lysostaphin and enterolysin-A). This probably indicates that this ECD and other
domains present in VALs might have evolved to efficiently compromise the PG of bacterial cells from
without to maintain phage infectivity. If true, VALs may possess superior antibacterial activity than
some endolysins and play a more decisive role for applications in vivo against pathogenic bacteria.
Moreover, ECDs from VALs may present increased thermostability when compared to those derived
from endolysins [32,37,42,71], which may result in prolonged shelf life.
4.2.3. Engineered Lytic Enzymes
The possibility of modifying native VALs and endolysins, or of using them as scaffolds to create
completely new enzybiotics, may provide additional solutions to overcome the described obstacles
of the field. Protein engineering is a growing trend in the area of phage lytic enzymes as it has been
showing the potential to generate enzymes with several improved features. These include not only
enhanced bactericidal activity against bacteria in different metabolic states and environments but also
expansion of the lytic spectrum and increased solubility, stability and circulating half-life. As already
mentioned, there are several strategies to tailor enzymes, namely domain deletion, addition, swapping
and site-directed modifications. Aleatory exchange of functional domains or random mutagenesis,
coupled to high-throughput screening methods, have also been used to select enzybiotics with
upgraded characteristics (for a recent review on enzybiotics engineering see [51]). These approaches
could benefit from ex-vivo screening procedures closely mimicking the targeted human conditions.
The VAL-derived chimeolysins EC300 and P128 are good examples of novel enzybiotics that efficiently
kill cells actively growing in complex media [43]. This breakthrough encourages the creation of new
tailor-made proteins using not only VAL domains but also other agents known to act from without such
as bacteriocins, antimicrobial peptides and bacteriolysins. Recent developments have also uncovered
the potential of engineered, phage-derived lytic enzymes to target intracellular pathogens [95,127].
In summary, artificial enzybiotics may provide a way to circumvent some of the limitations described
for native enzymes when applied in vivo.
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5. Conclusions and Perspectives
The demonstration of the bactericidal activity of phage PG-degrading enzymes has sparked the
interest for their exploration as alternatives or complements to existing antibiotics, particularly in the
current context of uncontrolled dissemination of antimicrobial drug resistance. These enzybiotics are
nontoxic, they usually have a narrow lytic spectrum and display quick bactericidal kinetics with low
probability of resistance development. The first demonstration of the therapeutic potential of phage
endolysins was followed by almost two decades dedicated to the discovery of new lytic agents and
their study in vitro and in animal models. Therefore, it was expected that a higher number of these
enzymes would have already made the transition from the proof-of-principle phase to the clinical stage.
After carefully reviewing the literature, we came to the conclusion that most endolysins have been
tested in conditions that are a poor approximation of real life bacterial infection scenarios. This might
account in part for some failures when the enzymes are tested in vivo and various suggestions are
given for testing them in more complex and realistic environments. In addition, we suggest VALs
as another class of PG-degrading enzymes that deserve further attention as they seem to present
natural advantages when compared to endolysins. Finally, in recent years this field of research has
been gradually moving to the modification of native lytic enzymes and to the generation of new and
improved enzybiotics through protein engineering techniques. This new era has been delivering
promising results and clues to overcome the limitations of native enzymes.
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